Home » Tonix Pharmaceuticals Completes Pharmacokinetic Study on New Formulation of TNX-102 for Fibromyalgia
Tonix Pharmaceuticals Completes Pharmacokinetic Study on New Formulation of TNX-102 for Fibromyalgia
Tonix Pharmaceuticals completed a pharmacokinetic study of the first formulation of its lead drug, TNX-102, for the treatment of fibromyalgia syndrome.
MarketWatch
MarketWatch
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May